They also suggest PPARα as a new therapeutic target for neurodegenerative diseases of metabolic origin, including AMD, a leading cause of blindness in the elderly [10], and potentially in retinal degenerations [11]. The gene discussed is PPARA; the disease is age-related macular degeneration.